MAIA Biotechnology (MAIA) announced dosing of the first patient in Taiwan in the expansion phase of its THIO-101 Phase 2 trial for advanced non-small cell lung cancer. The trial’s entry into another continent marks a milestone for MAIA, opening a significantly larger patient pool for its evaluations of ateganosine. Screening for the trial is ongoing in Europe and Asia.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAIA: